An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-nave EGFR-mutant Locally Advanced or Metastatic NSCLC
Study of Combining Osimertinib with and without Ramucirumab in Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Hoosier Cancer Research Network
Enrolling: Male and Female Patients
IRB Number: AAAT1153
U.S. Govt. ID: NCT03909334
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the usual treatment for Non-Small Cell Lung Cancer (osimertinib) to a combination therapy (osimertinib plus ramucirumab). The combination therapy arm is testing if ramucirumab can help osimertinib control the abnormal EGRG protein for a longer time and keep the disease inactive longer. EGRF protein typically helps the cell grow and divide and some subjects with Non-Small Cell Lung Cancer (NSCLC) have too much of this protein causing the cancer to grow faster. Osimertinib is an FDA approved drug that helps shrink the tumor by blocking the EGRF protein. This study has two arms, and subjects will be assigned randomly. One arm will receive Osimertinib by mouth and the other arm will receive Osimertinib by mouth along with ramucirumab intravenously (through an IV).
Investigator
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have confirmed non-squamous, non-small cell lung cancer? Yes No
Are you able to take pills by mouth? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162